Reporting of human cystic echinococcosis in Spain: how effective is the epidemiological surveillance system?

et al. Incidence and treatment of complications of bacillus Calmette-Guerı́n intravesical therapy in superficial bladder cancer. J Urol. 1992;147:596–600. 6. Van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 1995;27:23–8. 7. Rodrı́guez F, Palou J, Martı́nez R, Rodrı́guez O, Rosales A, Huguet J, et al. Esquema práctico del manejo de los efectos adversos asociados con la instilación de BCG. Arch Esp Urol. 2008;61(5):591–6. 8. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials. BJU Int. 2004;93:485–90. M. Isabel Cameo a, , M. Antonia Lezcano , Desirée Gil b y Miguel Blas c Servicio de Microbiologı́a, Hospital Universitario Miguel Servet, Zaragoza, España Servicio de Medicina Interna, Enfermedades Infecciosas, Hospital Universitario Miguel Servet, Zaragoza, España Servicio de Urologı́a, Hospital Universitario Miguel Servet, Zaragoza, España